The described genetic and preclinical findings are of significant relevance for potential TAAR1 agonist therapeutics since obesity, hyperglycemia, insulin resistance and dyslipidemia constitute major side effects of current antipsychotic drug (APD) classes [[23], [24], [25], [26]]. This evidence concerns the gene TAAR1 and obesity disorder.